BOUNDLESS BIO, INC. Increase (Decrease) in Accounts Payable and Accrued Liabilities
BOUNDLESS BIO, INC. (BOLD) reported Increase (Decrease) in Accounts Payable and Accrued Liabilities of -$1.60 million for the 6-month period ending 2026-06-30, per its 10-Q filed 2026-08-07.
Financial Statements › Cash Flow › Operating Activities
us-gaap:IncreaseDecreaseInAccountsPayableAndAccruedLiabilities · last filed 2026-08-07
- BOUNDLESS BIO, INC. increase (decrease) in accounts payable and accrued liabilities for the quarter ending 2026-06-30 was $1.47M, a 22.52% increase year-over-year.
- BOUNDLESS BIO, INC. increase (decrease) in accounts payable and accrued liabilities for the quarter ending 2026-03-31 was -$3.07M.
- BOUNDLESS BIO, INC. increase (decrease) in accounts payable and accrued liabilities for the quarter ending 2025-12-31 was $977.00K.
- BOUNDLESS BIO, INC. increase (decrease) in accounts payable and accrued liabilities for the quarter ending 2025-09-30 was $1.54M, a 13.62% decline year-over-year.
- BOUNDLESS BIO, INC. increase (decrease) in accounts payable and accrued liabilities for fiscal 2025 was $1.63M, a 110.84% increase from fiscal 2024.
- BOUNDLESS BIO, INC. increase (decrease) in accounts payable and accrued liabilities for fiscal 2024 was $775.00K, a 53.40% decline from fiscal 2023.
- BOUNDLESS BIO, INC. increase (decrease) in accounts payable and accrued liabilities for fiscal 2023 was $1.66M.
| Period end | Increase (Decrease) in Accounts Payable and Accrued Liabilities 3 month | Increase (Decrease) in Accounts Payable and Accrued Liabilities 6 month | Increase (Decrease) in Accounts Payable and Accrued Liabilities 9 month | Increase (Decrease) in Accounts Payable and Accrued Liabilities 12 month |
|---|---|---|---|---|
| 2026-06-30 | $1.47M derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-07 | -$1.60M 10-Q · filed 2026-08-07 | -$625.00K derived: sum of 3 quarters · filed 2026-08-07 | $916.00K derived: sum of 4 quarters · filed 2026-08-07 |
| 2026-03-31 | -$3.07M 10-Q · filed 2026-05-08 | -$2.09M derived: sum of 2 quarters · filed 2026-05-08 | -$553.00K derived: sum of 3 quarters · filed 2026-05-08 | $646.00K derived: sum of 4 quarters · filed 2026-08-07 |
| 2025-12-31 | $977.00K derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-09 | $2.52M derived: sum of 2 quarters · filed 2026-03-09 | $3.72M derived: sum of 3 quarters · filed 2026-08-07 | $1.63M 10-K · filed 2026-03-09 |
| 2025-09-30 | $1.54M derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-05 | $2.74M derived: sum of 2 quarters · filed 2026-08-07 | $657.00K 10-Q · filed 2025-11-05 | -$1.39M derived: sum of 4 quarters · filed 2026-08-07 |
| 2025-06-30 | $1.20M derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-07 | -$884.00K 10-Q · filed 2026-08-07 | -$2.93M derived: sum of 3 quarters · filed 2026-08-07 | -$1.15M derived: sum of 4 quarters · filed 2026-08-07 |
| 2025-03-31 | -$2.08M 10-Q · filed 2026-05-08 | -$4.13M derived: sum of 2 quarters · filed 2026-05-08 | -$2.35M derived: sum of 3 quarters · filed 2026-05-08 | -$1.10M derived: sum of 4 quarters · filed 2026-05-08 |
| 2024-12-31 | -$2.05M derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-09 | -$262.00K derived: sum of 2 quarters · filed 2026-03-09 | $985.00K derived: sum of 3 quarters · filed 2026-03-09 | $775.00K 10-K · filed 2026-03-09 |
| 2024-09-30 | $1.78M derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-05 | $3.03M derived: sum of 2 quarters · filed 2025-11-05 | $2.82M 10-Q · filed 2025-11-05 | $3.37M derived: sum of 4 quarters · filed 2025-11-05 |
| 2024-06-30 | $1.25M derived: 10-Q 6 month − 10-Q 3 month · filed 2025-08-05 | $1.04M 10-Q · filed 2025-08-05 | $1.59M derived: sum of 3 quarters · filed 2025-08-05 | $2.44M derived: sum of 4 quarters · filed 2025-08-05 |
| 2024-03-31 | -$210.00K 10-Q · filed 2025-05-09 | $339.00K derived: sum of 2 quarters · filed 2025-05-09 | $1.19M derived: sum of 3 quarters · filed 2025-05-09 | $2.36M derived: sum of 4 quarters · filed 2025-05-09 |
| 2023-12-31 | $549.00K derived: 10-K 12 month − 10-Q 9 month · filed 2025-03-27 | $1.40M derived: sum of 2 quarters · filed 2025-03-27 | $2.57M derived: sum of 3 quarters · filed 2025-03-27 | $1.66M 10-K · filed 2025-03-27 |
| 2023-09-30 | $855.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2024-11-07 | $2.02M derived: sum of 2 quarters · filed 2024-11-07 | $1.11M 10-Q · filed 2024-11-07 | |
| 2023-06-30 | $1.16M derived: 10-Q 6 month − 10-Q 3 month · filed 2024-08-12 | $259.00K 10-Q · filed 2024-08-12 | ||
| 2023-03-31 | -$904.00K 10-Q · filed 2024-05-13 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| NOMAD POWER SOLUTIONS, INC. (NMAD) | United States | $0.058B | |
| TALPHERA, INC. (TLPH) | United States | $0.060B | |
| CalciMedica, Inc. (CALC) | United States | $0.061B | -1.42 |
| Skye Bioscience, Inc. (SKYE) | United States | $0.061B | -0.48 |
| Annovis Bio, Inc. (ANVS) | United States | $0.056B | -1.58 |
| HERON THERAPEUTICS, INC. /DE/ (HRTX) | United States | $0.055B | -2.38 |
| Rein Therapeutics, Inc. (RNTX) | United States | $0.063B | -1.76 |
| Clene Inc. (CLNN) | United States | $0.054B | -1.99 |
| Serina Therapeutics, Inc. (SER) | United States | $0.054B | -2.35 |
| HYPERION DEFI, INC. (HYPD) | United States | $0.065B |